Portfolio company
Clementia
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Clementia develops drugs for rare bone diseases, including fibrodysplasia ossificans progressiva, for patients with these life-altering conditions.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Promedior
This biotechnology company develops drug therapies to treat rare fibrotic diseases for patients with conditions such as idiopathic pulmonary fibrosis and myelofibrosis.
Mereo BioPharma
The company develops clinical-stage therapies for patients with rare diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.
Castle Creek Biosciences
This company develops cell and gene therapies for patients suffering from rare genetic skin and connective tissue diseases.
Curzion Pharmaceuticals
This biopharmaceutical company develops oral small molecule therapies to treat patients with rare fibrotic conditions like diffuse cutaneous systemic sclerosis.
Angitia Biopharmaceuticals
The company develops biologic therapies for patients with serious musculoskeletal diseases, including osteoporosis and osteogenesis imperfecta.
Alesta Therapeutics
This biotechnology company develops oral small molecule therapies for patients with rare genetic disorders including hypophosphatasia and Charcot-Marie-Tooth disease.
Forma Therapeutics
This company develops medicines for patients with sickle cell disease and rare blood disorders.
AgomAb Therapeutics
This biopharmaceutical company develops therapies to treat fibrotic and inflammatory diseases for patients with conditions such as Crohn's disease and pulmonary fibrosis.